News & Videos - ENDO INTERNATIONAL PLC

Endo, Inc. Announces Pricing of $1.5 billion of Senior Secured Term Loan as Part of Endo's $2.5 billion Exit Financing PR Newswire MALVERN, Pa., April 12, 2024 MALVERN, Pa. , April 12, 2024 /PRNewswire/ -- Endo, Inc. ("Endo"), a newly formed entity, today announced that its wholly-owned subsidiary Endo Finance Holdings, Inc. (the "Borrower") priced its $1,500.0 million senior secured seven-year term loan (the "Term Loan"). To optimize the exit financing transactions, the Borrower has (i)...

Endo, Inc. Announces Pricing of $1.0 billion of Senior Secured Notes PR Newswire MALVERN, Pa., April 12, 2024 Offering Part of Endo's $2.5 billion Exit Financing MALVERN, Pa. , April 12, 2024 /PRNewswire/ -- Endo, Inc. ("Endo"), a newly formed entity, today announced that its wholly-owned subsidiary Endo Finance Holdings, Inc. (the "Issuer") priced $1,000.0 million aggregate principal amount of its 8.500% senior secured notes due 2031 (the "Notes"). To optimize the exit financing transactions,...

Endo, Inc. Announces Proposed Private Offering of Senior Secured Notes PR Newswire MALVERN, Pa., April 8, 2024 Part of Endo's $2.5 Billion Exit Financing MALVERN, Pa. , April 8, 2024 /PRNewswire/ -- Endo, Inc. ("Endo"), a newly formed entity, today announced that its wholly-owned subsidiary Endo Finance Holdings, Inc. (the "Issuer") intends to offer senior secured notes (the "Notes"), subject to market and customary conditions. The Notes will be senior secured obligations of the Issuer and will...

Endo, Inc. Announces Proposed New Senior Secured Credit Facilities PR Newswire MALVERN, Pa., April 1, 2024 MALVERN, Pa. , April 1, 2024 /PRNewswire/ -- Endo, Inc. ("Endo"), a newly formed entity, today announced that its wholly-owned subsidiary Endo Finance Holdings, Inc. (the "Borrower") intends to enter into new senior secured credit facilities consisting of: (i) a $400.0 million five-year super-priority revolving credit facility (the "New Revolving Facility"); and (ii) a $1,250.0 million...

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS® PR Newswire DUBLIN, March 26, 2024 DUBLIN , March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS ® . "We're proud to provide affordable choices to healthcare providers and their appropriate patients while...

Endo Announces Confirmation of Plan of Reorganization PR Newswire DUBLIN, March 19, 2024 Anticipates Completing Financial Restructuring as Early as Late April 2024 DUBLIN , March 19, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) ("Endo" or the "Company") today announced that the United States Bankruptcy Court for the Southern District of New York has confirmed its Chapter 11 plan of reorganization (the "Plan"), clearing the path for the Company to successfully complete its financial...

Endo Announces Confirmation of Plan of Reorganization PR Newswire DUBLIN, March 19, 2024 Anticipates Completing Financial Restructuring as Early as Late April 2024 DUBLIN , March 19, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) ("Endo" or the "Company") today announced that the United States Bankruptcy Court for the Southern District of New York has confirmed its Chapter 11 plan of reorganization (the "Plan"), clearing the path for the Company to successfully complete its financial...

Par Pharmaceutical Issues Voluntary Nationwide Recall of One Lot of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution PR Newswire DUBLIN, March 12, 2024 DUBLIN , March 12, 2024 /PRNewswire/ -- Endo International plc announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), is voluntarily recalling one lot of Treprostinil Injection 20mg/20mL (1mg/mL) to the consumer level. The product is being recalled due to the potential for the...

ENDO REPORTS FOURTH-QUARTER 2023 FINANCIAL RESULTS PR Newswire DUBLIN, March 6, 2024 DUBLIN , March 6, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) today reported financial results for the fourth-quarter ended December 31, 2023 . FOURTH-QUARTER FINANCIAL PERFORMANCE (in thousands, except per share amounts) Three Months Ended December 31, Year Ended December 31, 2023 2022 Change 2023 2022 Change Total Revenues, Net $ 497,734 $ 555,812 (10) % $ 2,011,518 $ 2,318,875 (13) % Reported...

ENDO REPORTS FOURTH-QUARTER 2023 FINANCIAL RESULTS PR Newswire DUBLIN, March 6, 2024 DUBLIN , March 6, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) today reported financial results for the fourth-quarter ended December 31, 2023 . FOURTH-QUARTER FINANCIAL PERFORMANCE (in thousands, except per share amounts) Three Months Ended December 31, Year Ended December 31, 2023 2022 Change 2023 2022 Change Total Revenues, Net $ 497,734 $ 555,812 (10) % $ 2,011,518 $ 2,318,875 (13) % Reported...

Endo Reaches Resolution with U.S. Department of Justice Regarding Legacy Marketing of Opana® ER PR Newswire DUBLIN, Feb. 29, 2024 With This Resolution, Endo Prepares to Complete Its Financial Restructuring Positioned for Sustained Success DUBLIN , Feb. 29, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) ("Endo" or the "Company") today announced that its subsidiary, Endo Health Solutions Inc. ("EHSI"), has agreed to resolve all issues regarding previously disclosed U.S. Department of...

Endo Reaches Resolution with U.S. Department of Justice Regarding Legacy Marketing of Opana® ER PR Newswire DUBLIN, Feb. 29, 2024 With This Resolution, Endo Prepares to Complete Its Financial Restructuring Positioned for Sustained Success DUBLIN , Feb. 29, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) ("Endo" or the "Company") today announced that its subsidiary, Endo Health Solutions Inc. ("EHSI"), has agreed to resolve all issues regarding previously disclosed U.S. Department of...

Endo Announces Publication of New XIAFLEX® (collagenase clostridium histolyticum) Survey Data in Journal of Hand Surgery Global Open PR Newswire DUBLIN, Jan. 24, 2024 DUBLIN , Jan. 24, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the peer-reviewed Journal of Hand Surgery Global Open published Collagenase Clostridium Histolyticum for the Treatment of Dupuytren Disease: A Delphi-Based Consensus Study . 1 Consensus-based study findings among expert hand surgeons...

Endo's Paladin Labs Announces Launch of XCOPRI® (cenobamate tablets) in Canada PR Newswire MONTREAL, Jan. 22, 2024 MONTREAL , Jan. 22, 2024 /PRNewswire/ -- Paladin Labs Inc., a subsidiary of Endo International plc (OTC: ENDPQ), announced today that XCOPRI ® (cenobamate tablets) is now available in Canada . XCOPRI is indicated as adjunctive therapy in the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy. "We are pleased...

Endo Announces New Data for Dupuytren's Contracture Presented at the American Association for Hand Surgery Annual Meeting PR Newswire DUBLIN, Jan. 19, 2024 DUBLIN , Jan. 19, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that two new presentations related to Dupuytren's contracture and XIAFLEX ® (collagenase clostridium histolyticum) were shared during the American Association for Hand Surgery (AAHS) annual meeting. Endo provided funding through an...

ENDO FILES PLAN OF REORGANIZATION TO IMPLEMENT PREVIOUSLY ANNOUNCED SALE TRANSACTION PR Newswire DUBLIN, Dec. 19, 2023 Paves the Way for Endo to Successfully Conclude Financial Restructuring in Second Quarter of 2024 DUBLIN , Dec. 19, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) ("Endo" or the "Company") today announced that it has taken an important step toward concluding its financial restructuring process by filing a proposed Plan of Reorganization (the "Plan") and related...

ENDO FILES PLAN OF REORGANIZATION TO IMPLEMENT PREVIOUSLY ANNOUNCED SALE TRANSACTION PR Newswire DUBLIN, Dec. 19, 2023 Paves the Way for Endo to Successfully Conclude Financial Restructuring in Second Quarter of 2024 DUBLIN , Dec. 19, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) ("Endo" or the "Company") today announced that it has taken an important step toward concluding its financial restructuring process by filing a proposed Plan of Reorganization (the "Plan") and related...

Endo Launches Unscripted Video Series With Real Peyronie's Disease Patients PR Newswire DUBLIN, Nov. 30, 2023 "PD Pool Hall" Explores the Men's Health Condition Through Real Patients and Real Talk Unscripted videos feature real Peyronie's disease (PD) patients discussing their experiences while shooting pool Though PD is a relatively common condition, diagnosis rates remain low because men with PD may be uncomfortable to speak up and get help "PD Pool Hall" videos are available online now and...

Endo Announces Five Presentations at the Sexual Medicine Society of North America (SMSNA) Annual Meeting PR Newswire DUBLIN, Nov. 16, 2023 DUBLIN , Nov. 16, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that five new presentations related to Peyronie's disease, or PD, and XIAFLEX ® (collagenase clostridium histolyticum, or CCH, injection 0.9 mg) will be shared during the Sexual Medicine Society of North America (SMSNA) annual meeting, taking place November 16-19 in...

ENDO REPORTS THIRD-QUARTER 2023 FINANCIAL RESULTS PR Newswire DUBLIN, Nov. 6, 2023 DUBLIN , Nov. 6, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) today reported financial results for the third-quarter ended September 30, 2023 . THIRD-QUARTER FINANCIAL PERFORMANCE (in thousands, except per share amounts) Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 Change 2023 2022 Change Total Revenues, Net $ 451,665 $ 541,690 (17) % $ 1,513,784 $ 1,763,063 (14) %...